Tuesday November 15, 2022
XF-73 Dermal infection project advances into clinically enabling safety study with US Go...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) XF-73 Dermal infection project advances into clinically enabling safety study as part of ongoing agreement with US Government’s NIAID Brighton, United Kingdom, […]
Monday November 14, 2022
New report highlights fast growing market for Live Biotherapeutics, Destiny Pharma’...
A new report highlights a fast growing market for Live Biotherapeutics, reaching $2.6bn by 2030. Destiny Pharma’s NTCD-M3 preventing C. difficile infections is leading play in this sector. View the […]
Wednesday October 19, 2022
Destiny Pharma R&D Investor Update meeting presentation recording
Destiny Pharma’s R&D Investor Update meeting, held on Tuesday 18 October 2022, is now available to watch via the link below:- R&D Investor Update meeting presentation
Thursday September 8, 2022
Interim results for six months ended 30 June 2022
Destiny Pharma today announced its interim results for the 6 months ended 30 June 2022, which can be found here.
Wednesday September 7, 2022
Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Inves...
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma CEO, Neil Clark, to present at the HC Wainwright 24th Annual Global Investment Conference Brighton, United Kingdom – 7 September 2022 – […]
Wednesday September 7, 2022
Positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Destiny Pharma announces positive update from European Medicine Agency (EMA) on NTCD-M3 Phase 3 development plans EMA endorses Destiny Pharma’s proposed single […]
Monday August 22, 2022
Notice of Interim Results and Investor Presentation
Destiny Pharma plc (“Destiny Pharma” or the “Company”) Notice of Interim Results and Investor Presentation Brighton, United Kingdom ‐ 22 August 2022 ‐ Destiny Pharma plc (AIM: DEST), a clinical […]
Thursday July 28, 2022